Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 681 to 690 of 2234 total matches.

Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
by the FDA for PTCL. The first was the antifolate drug pralatrexate (Folotyn),1 which was followed ...
The FDA has approved belinostat (Beleodaq – Spectrum), an IV histone deacetylase (HDAC) inhibitor, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the third IV drug approved by the FDA for PTCL. The first was the antifolate drug pralatrexate (Folotyn), which was followed by the HDAC inhibitor romidepsin (Istodax). Vorinostat (Zolinza), an oral HDAC inhibitor, is FDA-approved for treatment of cutaneous T-cell lymphoma.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):66-7 | Show Introduction Hide Introduction

Pomalidomide (Pomalyst) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
on days 1-21 of a 28-day cycle alone or combined with 40 mg/week of dexamethasone. Progression-free ...
The FDA has approved pomalidomide (Pomalyst – Celgene), an oral thalidomide analog, for treatment of patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide (Revlimid) and bortezomib (Velcade) and whose disease had progressed on or within 60 days of completion of the last therapy.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):66-7 | Show Introduction Hide Introduction

Ivermectin Cream (Soolantra) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015  (Issue 1466)
' tra The FDA has approved a 1% cream formulation of the antiparasitic drug ivermectin (Soolantra ...
The FDA has approved a 1% cream formulation of the antiparasitic drug ivermectin (Soolantra – Galderma) for topical treatment of inflammatory lesions of rosacea. Ivermectin is available in the US in tablets (Stromectol, and generics) for treatment of onchocerciasis and other worm infestations and as a 0.5% lotion (Sklice) for treatment of head lice.
Med Lett Drugs Ther. 2015 Apr 13;57(1466):51-2 | Show Introduction Hide Introduction

In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015  (Issue 1466)
, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...
Med Lett Drugs Ther. 2015 Apr 13;57(1466):58 | Show Introduction Hide Introduction

Gardasil 9 - A Broader HPV Vaccine

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
disease associated with HPV types 6, 11, 16, and 18,1 and Cervarix prevents disease associated with HPV ...
The FDA has now approved a recombinant, 9-valent, human papillomavirus (HPV) vaccine (Gardasil 9 – Merck) for use in girls and women 9-26 years old and boys 9-15 years old. The new vaccine is indicated to prevent diseases associated with infection with HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which include genital warts and cervical, vulvar, vaginal, and anal precancerous lesions and cancer. Two recombinant HPV vaccines are already available in the US: Gardasil prevents disease associated with HPV types 6, 11, 16, and 18, and Cervarix prevents disease associated with HPV...
Med Lett Drugs Ther. 2015 Mar 30;57(1465):47-8 | Show Introduction Hide Introduction

OTC Fluticasone Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
(Nasacort Allergy 24HR) was the first.1 Unlike prescription Flonase, the OTC product is FDA-approved ...
The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription product (Flonase, and generics) for patients ≥4 years old with seasonal or perennial allergic rhinitis. It is the second corticosteroid nasal spray to become available OTC; triamcinolone acetonide (Nasacort Allergy 24HR) was the first. Unlike prescription Flonase, the OTC product is FDA-approved for reduction of ocular as well as nasal symptoms. Brand-name prescription Flonase has been...
Med Lett Drugs Ther. 2015 Mar 30;57(1465):48-9 | Show Introduction Hide Introduction

Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
usually continues for at least 3 months.1,2 In patients with nonvalvular atrial fibrillation, dabigatran ...
The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):43-5 | Show Introduction Hide Introduction

Secukinumab (Cosentyx) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
associated with multiple comorbidities.1 Topical preparations, including corticosteroids and vitamin D ...
Secukinumab (Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It is the first IL-17 inhibitor to be approved for any indication in the US.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):45-7 | Show Introduction Hide Introduction

Spiriva Respimat - An Oral Inhalation Spray for COPD

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
obstructive pulmonary disease (COPD),1 has now also been approved in an inhalation spray formulation ...
Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD), has now also been approved in an inhalation spray formulation (Spiriva Respimat – Boehringer Ingelheim). According to the manufacturer, the Respimat device improves delivery of tiotropium to the lungs because, unlike with the Handihaler, it is not dependent on the strength of the patient’s breath intake.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):49-50 | Show Introduction Hide Introduction

VEGF Inhibitors for AMD and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2015  (Issue 1464)
, it appeared to be similar to ranibizumab in effectiveness.5 A large 1-year study sponsored by the NIH ...
Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular permeability and inflammation. VEGF inhibitors reduce leakage from blood vessels, prevent proliferation of new abnormal vessels, decrease swelling of the retina, and improve visual acuity in patients with neovascular (wet) AMD and diabetic macular edema. These drugs are given as periodic intravitreal injections with topical anesthesia.
Med Lett Drugs Ther. 2015 Mar 16;57(1464):41-2 | Show Introduction Hide Introduction